FIGURE 3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Expression of protein markers significantly altered by treatment with eribulin in combination with copanlisib in all PDX models. A, Expression of RPPA protein markers significantly altered, with FDR-adjusted P value B, Heat map of estimated coefficient for FDR significantly altered markers (P